Durvalumab (Imfinzi) plus enfortumab vedotin (Padcev) cuts death risk 42% in bladder cancer trial

Study · The Pharmaletter · 2026-10-26. Number 3 in the UrologyWatch Top 5 for October 28, 2026.

A trial of durvalumab (Imfinzi) plus enfortumab vedotin (Padcev) reported a 42% reduction in death risk in bladder cancer, though the report notes it trails the pembrolizumab (Keytruda)-based combination.

Why it matters: Adds a second checkpoint-inhibitor/ADC combination with a reported survival benefit in advanced urothelial cancer, though cross-trial comparisons are not definitive.

Limitation: Cross-trial comparison with a different regimen is not a head-to-head comparison; details of patient population and endpoints should be confirmed in full publication.

Source: The Pharmaletter

The full October 28, 2026 edition · Today's urology news